![]() That includes patients taking RPT193 reporting a 53.2% improvement. In the two weeks following the four weeks of treatments, further improvements were seen. RAPT Therapeutics notes that the positive news continues beyond just the treatment period. For comparison, placebo improvement was 17%. ![]() ![]() After four weeks of treatment, patients taking RPT193 saw an improvement of 36.3% on the Eczema Area and Severity Index score. The clinical trial included a total of 31 patients suffering from moderate-to-severe atopic dermatitis. The recent results come from a Phase 1b clinical trial of the drug. RPT193 is the company’s treatment in development designed to treat patients suffering from moderate-to-severe atopic dermatitis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |